Adrian Pharmaceuticals

Adrian Pharmaceuticals is a French clinical-stage biotechnology company focused on developing innovative therapies in oncology, specifically in the field of radiosensitization. The company's primary mission is to enhance the efficacy of radiotherapy for patients with aggressive solid tumors that are resistant to standard treatments due to hypoxia. Its lead product candidate, AD-01, is a proprietary oral formulation of nimorazole designed to target hypoxic cancer cells and sensitize them to radiation-induced DNA damage. Adrian Pharmaceuticals is currently evaluating AD-01 in clinical trials for high-unmet-need indications, including glioblastoma and brain metastases. By addressing the limitations of current radiation therapy, the company aims to improve survival rates and quality of life for cancer patients. Headquartered in France, the company is led by a team with extensive experience in pharmaceutical development and oncology.